Observational studyFrontiers in endocrinology2026
Study on the correlation between hyperuricemia and components of metabolic syndrome in T2DM in China: a single-center, observational study.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperuricemia (HUA) and metabolic syndrome (MetS) are increasingly prevalent and closely related. This single-center, retrospective study aims to explore the correlation between HUA and individual MetS components in Chinese patients with type 2 diabetes mellitus (T2DM), and further explores its potential influence on bone metabolism indicators. Method: This retrospective study included patients age 18-80 attending Peking University Shenzhen Hospital from March 1, 2023 to May 31, 2024. 426 HUA patients and 1437 normouricemia (NUA) patients were collected and completed clinical and biochemical measurements. Spearman correlation, logistic regression, multiple linear regression, and subgroup analysis were used to verify the relationship between HUA and MetS components (including obesity, hypertension, hyperglycemia, and dyslipidemia). A nomogram and ROC curve were established to identify predictors of HUA risk. Result: The prevalence of HUA was 22.86%. Spearman analysis showed that BMI (r = 0.322) and TG (r = 0.304) had moderate positive correlations with SUA; sex [female%] exhibited a moderate inverse correlation (r = -0.444). HDL-C (r = -0.218) and eGFR (r = -0.283) showed weak inverse correlations. N-MID (r = -0.049) and P1NP (r = -0.063) showed negligible correlations with SUA, despite statistical significance. Binary logistic regression identified female sex, HbA1c, and eGFR as factors associated with lower HUA risk, while BMI, DBP, TG, and 25(OH)D were associated with increased risk. ROC analysis demonstrated moderate predictive value for BMI (AUC = 0.647), DBP (AUC = 0.602), and 25(OH)D (AUC = 0.578) (all P < 0.001). TG showed an AUC of 0.650 but was not statistically significant (P = 0.502). eGFR (AUC = 0.364) and HbA1c (AUC = 0.489) performed worse than random chance. Multiple linear regression revealed weak positive associations of SUA with BMI (β = 0.211) and TG (β = 0.151), weak inverse associations with HbA1c (β = -0.153) and HDL-C (β = -0.160), and a negligible association with 25(OH)D (β = 0.055). Subgroup analysis indicated higher HUA risk in males and those with metabolic abnormalities. Conclusion: This exploratory study identifies moderate predictive value of BMI, DBP, and 25(OH)D for HUA in Chinese T2DM patients, and a substantially lower risk in females. TG was not an independent predictor. Associations with bone markers and 25(OH)D were negligible. These findings highlight modest interconnections between HUA and metabolic dysregulation, particularly obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.